ABUS:NSD-Arbutus Biopharma Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.62

Change

+0.09 (+1.99)%

Market Cap

USD 0.45B

Volume

2.85M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A

ETFs Containing ABUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.14% 78% C+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.14% 78% C+ 75% C
Trailing 12 Months  
Capital Gain 50.00% 73% C 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 73% C 61% D-
Trailing 5 Years  
Capital Gain 16.67% 59% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.67% 58% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 32.23% 64% D 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.23% 64% D 76% C
Risk Return Profile  
Volatility (Standard Deviation) 83.10% 37% F 21% F
Risk Adjusted Return 38.79% 64% D 55% F
Market Capitalization 0.45B 55% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.44 70% C- 54% F
Price / Cash Flow Ratio -8.73 54% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.05% 31% F 20% F
Return on Invested Capital -65.56% 36% F 13% F
Return on Assets -34.75% 28% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.68 69% D+ 57% F
Short Percent 5.33% 51% F 33% F
Beta 2.90 3% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector